Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
Abstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-018-0910-3 |
id |
doaj-61246be1c13049cd804b25277800053f |
---|---|
record_format |
Article |
spelling |
doaj-61246be1c13049cd804b25277800053f2020-11-24T21:23:59ZengBMCBMC Ophthalmology1471-24152018-09-011811610.1186/s12886-018-0910-3Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye diseaseYongseok Mun0Ji-Won Kwon1Joo Youn Oh2Department of Ophthalmology, Seoul National University HospitalDepartment of ophthalmology, Hanyang University College of Medicine Myongji HospitalDepartment of Ophthalmology, Seoul National University HospitalAbstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value ≤5 s, corneoconjunctival staining score ≤ 2 (on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not. Results Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 ± 27.5 vs. 63.3 ± 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2). Conclusions Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients. Trial registration The study was retrospectively registered on Clinical Research Information Service (CRiS), Republic of Korea. Trial registration number: KCT0003134. Date of registration: 2018-08-15.http://link.springer.com/article/10.1186/s12886-018-0910-3Diquafosol tetrasodium 3%Dry eye diseaseShort tear film break-up time-type dry eye |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yongseok Mun Ji-Won Kwon Joo Youn Oh |
spellingShingle |
Yongseok Mun Ji-Won Kwon Joo Youn Oh Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease BMC Ophthalmology Diquafosol tetrasodium 3% Dry eye disease Short tear film break-up time-type dry eye |
author_facet |
Yongseok Mun Ji-Won Kwon Joo Youn Oh |
author_sort |
Yongseok Mun |
title |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
title_short |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
title_full |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
title_fullStr |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
title_full_unstemmed |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
title_sort |
therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease |
publisher |
BMC |
series |
BMC Ophthalmology |
issn |
1471-2415 |
publishDate |
2018-09-01 |
description |
Abstract Background To investigate therapeutic effects of topical diquafosol tetrasodium 3% ophthalmic solution in patients with short tear film break-up time (TFBUT)-type dry eye (DE). Methods The prospective study was performed in 70 eyes of 70 patients with short TFBUT-type DE. Diagnosis of short TFBUT-type DE was made based on the presence of DE symptoms, TFBUT value ≤5 s, corneoconjunctival staining score ≤ 2 (on a scale of 0 to 4), and Schirmer I value > 5 mm. Patients with systemic immunologic disorders or ocular graft-versus-host disease were excluded. Before and after instillation of 3% diquafosol ophthalmic solution six times per day for 4 weeks, subjective DE symptoms, TFBUT, corneoconjunctival staining score, and Schirmer I value were examined and compared. Also, demographic factors were compared between patients who showed improvement in each DE parameter by treatment and those who did not. Results Four-week treatment with 3% diquafosol ophthalmic solution significantly improved DE symptoms (p < 0.0001), increased TFBUT (p < 0.0001), and reduced corneoconjunctival staining scores (p < 0.0001). Schirmer I values were not changed by treatment. The age of patients who showed improvement in subjective DE symptoms after treatment was significantly lower than that of patients who did not (53.4 ± 27.5 vs. 63.3 ± 13.9 years, p = 0.012). Ocular side effects developed in 3 patients (4.3%), including conjunctival chemosis (n = 1) and persistent stinging sensation (n = 2). Conclusions Diquafosol tetrasodium 3% ophthalmic solution is effective in improving subjective symptoms and tear film stability in short TFBUT-type DE patients. Trial registration The study was retrospectively registered on Clinical Research Information Service (CRiS), Republic of Korea. Trial registration number: KCT0003134. Date of registration: 2018-08-15. |
topic |
Diquafosol tetrasodium 3% Dry eye disease Short tear film break-up time-type dry eye |
url |
http://link.springer.com/article/10.1186/s12886-018-0910-3 |
work_keys_str_mv |
AT yongseokmun therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease AT jiwonkwon therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease AT jooyounoh therapeuticeffectsof3diquafosolophthalmicsolutioninpatientswithshorttearfilmbreakuptimetypedryeyedisease |
_version_ |
1725990120697364480 |